-
Find a Clinical Trial
-
Get Connected
-
Scientific Report
-
Get Involved
-
About MRA
Is AI the future of detecting melanoma early, when it is easiest to cure?
Brain metastases (mets) are a frequent and often deadly problem in patients with advanced melanoma. Nearly 40% of patients with metastatic melanoma have brain mets at diagnosis, with an average survival of only 4 months, highlighting a crucial need for treatments that can rid the brain of these tumors. Fortunately, MRA-funded researchers are making headway in understanding brain mets and how to best treat them.
We know that facing cancer requires enormous personal strength and that each person's inspiration is unique to them. That's why we're asking you to show how you harness your unique inner power to rise up against the disease by sharing a photo of you holding a sign that says #ReadyRaiseRise.
Melanoma is the deadliest form of skin cancer. Rates of melanoma are rising rapidly, especially in younger people. In fact, cases of melanoma have tripled in the last 30 years, at a time when cancer rates for other common cancers have declined.
Do you know the answer to these top ten questions people ask about melanoma?
Dr. Patrick Ott, Clinical Director of the Melanoma Center at the Dana-Farber Cancer Institute and lead researcher on the BJ's Wholesale Club-MRA Team Science Award, is conducting pioneering research to harness the power of personalized vaccines to combat melanoma.
